Which of the following patients is at greater risk for complications caused by the influenza virus

Many groups of people are at high risk of complications from influenza.

Persons considered to be at increased risk of complications from influenza include young children, pregnant women and postpartum women up to 2 weeks after delivery, older adults, people with certain chronic medical problems, people who live in nursing homes, and certain racial and ethnic minority groups. From 2009 to 2019, non-Hispanic Black people had the highest influenza hospitalization rates, followed by non-Hispanic American Indian or Alaska Native people, then Hispanic or Latino people, and then non-Hispanic White people.

Prevention of Influenza in High-risk Groups

The best way to prevent influenza is by getting an influenza vaccination each year. While everyone aged 6 months or older is recommended to receive influenza vaccination, it is particularly important for people who are at increased risk of complications. Most influenza vaccines are produced using influenza viruses grown in eggs. Several kinds of influenza vaccines are available that protect against 4 influenza A and B virus strains (quadrivalent vaccines), including inactivated standard-dose vaccines for people aged 6 months or older, live-attenuated vaccines for healthy nonpregnant people aged 2 to 49 years, tissue cell culture–grown and recombinant vaccines not produced in eggs that are options for people with severe egg allergies, and high-dose and adjuvanted vaccines for people aged 65 years or older that may improve immune response and vaccine effectiveness. Because people in certain minority groups may be at increased risk of influenza or developing severe illness, influenza vaccination is especially important for these communities. Influenza vaccination is recommended by the end of October, but unvaccinated persons are encouraged to receive vaccination in November and December, and later if influenza viruses are circulating and vaccine is available.

What Should People in High-risk Groups Do When Sick?

If respiratory illness symptoms begin during flu season, people who are at increased risk of complications should contact their primary care clinician right away. Fever is not always present with influenza in people of any age, especially in older adults and people with weakened immune systems.

Influenza can worsen underlying chronic medical conditions, such as chronic obstructive pulmonary disease, asthma, heart failure, and diabetes. A telemedicine appointment or an in-person visit can assess whether influenza or another cause might be responsible for a respiratory illness. A clinician can determine whether testing for influenza or other causes is needed.

Antiviral Treatment of Influenza in High-risk Groups

Antiviral treatment of influenza can reduce risk of some complications, especially when started within 2 days of symptom onset. Therefore, people in high-risk groups should contact their primary care clinician as soon as respiratory symptoms begin. If influenza is diagnosed and antiviral treatment is prescribed, patients should begin treatment as soon as possible.

Published Online: November 2, 2020. doi:10.1001/jama.2020.21869

Conflict of Interest Disclosures: None reported.

Disclaimer: The views expressed are those of the author and do not necessarily represent the official policy of the Centers for Disease Control and Prevention.

1. Thompson W.W., Shay D.K., Weintraub E. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–186. [PubMed] [Google Scholar]

2. Thompson W.W., Shay D.K., Weintraub E. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333–1340. [PubMed] [Google Scholar]

3. Simonsen L., Taylor R., Viboud C. US flu mortality estimates are based on solid science. BMJ. 2006;332:177–178. [PMC free article] [PubMed] [Google Scholar]

4. Simonsen L., Reichert T.A., Viboud C. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med. 2005;165:265–272. [PubMed] [Google Scholar]

5. Dushoff J., Plotkin J.B., Viboud C. Mortality due to influenza in the United States—an annualized regression approach using multiple-cause mortality data. Am J Epidemiol. 2006;163:181–187. [PubMed] [Google Scholar]

6. Rothberg M. Prioritizing influenza vaccination. JAMA. 2004;292:2582–2583. [PubMed] [Google Scholar]

7. Glezen W.P., Decker M., Perrotta D.M. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. Am Rev Respir Dis. 1987;136:550–555. [PubMed] [Google Scholar]

8. Izurieta H.S., Thompson W.W., Kramarz P. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342:232–239. [PubMed] [Google Scholar]

9. Smith N.M., Bresee J.S., Shay D.K. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2006;55:1–42. [PubMed] [Google Scholar]

10. Hak E., Wei F., Nordin J. Development and validation of a clinical prediction rule for hospitalization due to pneumonia or influenza or death during influenza epidemics among community-dwelling elderly persons. J Infect Dis. 2004;189:450–458. [PubMed] [Google Scholar]

11. Neuzil K.M., Reed G.W., Mitchel E.F. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol. 1998;148:1094–1102. [PubMed] [Google Scholar]

12. Schrag S.J., Fiore A.E., Gonik B. Vaccination and perinatal infection prevention practices among obstetrician-gynecologists. Obstet Gynecol. 2003;101:704–710. [PubMed] [Google Scholar]

13. Influenza vaccination in pregnancy: practices among obstetrician-gynecologists—United States, 2003-04 influenza season. MMWR Morb Mortal Wkly Rep. 2005;54:1050–1052. [PubMed] [Google Scholar]

14. Skiest D.J., Kaplan P., Machala T. Clinical manifestations of influenza in HIV-infected individuals. Int J STD AIDS. 2001;12:646–650. [PubMed] [Google Scholar]

15. Klein M.B., Lu Y., DelBalso L. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis. 2007;45:234–240. [PubMed] [Google Scholar]

16. Neuzil K.M., Reed G.W., Mitchel E.F., Jr, Griffin M.R. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA. 1999;281:901–907. [PubMed] [Google Scholar]

17. Fine A.D., Bridges C.B., De Guzman A.M. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis. 2001;32:1784–1791. [PubMed] [Google Scholar]

18. Lin J.C., Nichol K.L. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med. 2001;161:441–446. [PubMed] [Google Scholar]

19. Golden M.P., Sajjad Z., Elgart L. Influenza and human immunodeficiency virus infection: absence of HIV progression after acute influenza infection. Clin Infect Dis. 2001;32:1366–1370. [PubMed] [Google Scholar]

20. Whimbey E., Champlin R.E., Couch R.B. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22:778–782. [PubMed] [Google Scholar]

21. Vilchez R.A., McCurry K., Dauber J. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant. 2002;2:287–291. [PubMed] [Google Scholar]

22. Louria D.B., Blumenfeld H.L., Ellis J.T. Studies on influenza in the pandemic of 1957-1958: II. Pulmonary complications of influenza. J Clin Invest. 1959;38:213–265. [PMC free article] [PubMed] [Google Scholar]

23. Murata Y., Walsh E.E., Falsey A.R. Pulmonary complications of interpandemic influenza A in hospitalized adults. J Infect Dis. 2007;195:1029–1037. [PubMed] [Google Scholar]

24. Oliveira E.C., Marik P.E., Colice G. Influenza pneumonia: a descriptive study. Chest. 2001;119:1717–1723. [PubMed] [Google Scholar]

25. Noble R.L., Lillington G.A., Kempson R.L. Fatal diffuse influenzal pneumonia: premortem diagnosis by lung biopsy. Chest. 1973;63:644–646. [PubMed] [Google Scholar]

26. Peiris J.S., de Jong M.D., Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev. 2007;20:243–267. [PMC free article] [PubMed] [Google Scholar]

27. The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5 Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374–1385. [PubMed] [Google Scholar]

28. Treanor J. Influenza virus. In: Mandell G.L., Bennett J.E., Dolin R., editors. 6th ed. 162 vol. Churchill Livingstone; Philadelphia: 2005. pp. 2060–2085. (Principles and Practice of Infectious Diseases). [Google Scholar]

29. Schwarzmann S.W., Adler J.L., Sullivan R.J., Jr, Marine W.M. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch Intern Med. 1971;127:1037–1041. [PubMed] [Google Scholar]

30. Chickering H., Park J.H. Staphylococcus aureus pneumonia. JAMA. 1919;72:617–626. [Google Scholar]

31. Prechter G.C., Gerhard A.K. Postinfluenza toxic shock syndrome. Chest. 1989;95:1153–1154. [PubMed] [Google Scholar]

32. Hageman J.C., Uyeki T.M., Francis J.S. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis. 2006;12:894–899. [PMC free article] [PubMed] [Google Scholar]

33. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza—Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep. 2007;56:325–329. [PubMed] [Google Scholar]

34. McCullers J.A. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev. 2006;19:571–582. [PMC free article] [PubMed] [Google Scholar]

35. Lewis M., Kallenbach J., Ruff P. Invasive pulmonary aspergillosis complicating influenza A pneumonia in a previously healthy patient. Chest. 1985;87:691–693. [PubMed] [Google Scholar]

36. Boots R.J., Paterson D.L., Allworth A.M., Faoagali J.L. Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF. Thorax. 1999;54:1047–1049. [PMC free article] [PubMed] [Google Scholar]

37. Miyashita N., Matsushima T. Chlamydia pneumoniae infection during an influenza virus A epidemic: preliminary report. J Med Microbiol. 2000;49:391–392. [PubMed] [Google Scholar]

38. Gerber G.J., Farmer W.C., Fulkerson L.L. Beta-hemolytic streptococcal pneumonia following influenza. JAMA. 1978;240:242–243. [PubMed] [Google Scholar]

39. Garantziotis S., Howell D.N., McAdams H.P. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest. 2001;119:1277–1280. [PubMed] [Google Scholar]

40. Pinsker K.L., Schneyer B., Becker N., Kamholz S.L. Usual interstitial pneumonia following Texas A2 influenza infection. Chest. 1981;80:123–126. [PubMed] [Google Scholar]

41. Wilson C.B., Smith R.C. Goodpasture’s syndrome associated with influenza A2 virus infection. Ann Intern Med. 1972;76:91–94. [PubMed] [Google Scholar]

42. Rohde G., Wiethege A., Borg I. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax. 2003;58:37–42. [PMC free article] [PubMed] [Google Scholar]

43. Lin C.Y., Kuo Y.C., Liu W.T., Lin C.C. Immunomodulation of influenza virus infection in the precipitating asthma attack. Chest. 1988;93:1234–1238. [PubMed] [Google Scholar]

44. Foulkes W., Rees J., Sewry C. Influenza A and rhabdomyolysis. J Infect. 1990;21:303–304. [PubMed] [Google Scholar]

45. Studahl M. Influenza virus and CNS manifestations. J Clin Virol. 2003;28:225–232. [PubMed] [Google Scholar]

46. Hurwitz E.S., Nelson D.B., Davis C. National surveillance for Reye syndrome: a five-year review. Pediatrics. 1982;70:895–900. [PubMed] [Google Scholar]

47. Barr C.E., Mednick S.A., Munk-Jorgensen P. Exposure to influenza epidemics during gestation and adult schizophrenia: A 40-year study. Arch Gen Psychiatry. 1990;47:869–874. [PubMed] [Google Scholar]

48. Ison M.G., Campbell V., Rembold C. Cardiac findings during uncomplicated acute influenza in ambulatory adults. Clin Infect Dis. 2005;40:415–422. [PubMed] [Google Scholar]

49. Jefferson T.O., Rivetti D., Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2007 CD001269. [PubMed] [Google Scholar]

50. Rivetti D., Jefferson T., Thomas R. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2006;3:CD004876. [PubMed] [Google Scholar]

51. Castle S.C. Clinical relevance of age-related immune dysfunction. Clin Infect Dis. 2000;31:578–585. [PubMed] [Google Scholar]

52. Kang I., Hong M.S., Nolasco H. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J Immunol. 2004;173:673–681. [PubMed] [Google Scholar]

54. Jackson L.A., Jackson M.L., Nelson J.C. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol. 2006;35:337–344. [PubMed] [Google Scholar]

55. Mangtani P., Cumberland P., Hodgson C.R. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis. 2004;190:1–10. [PubMed] [Google Scholar]

56. Jackson L.A., Nelson J.C., Benson P. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol. 2006;35:345–352. [PubMed] [Google Scholar]

57. Simonsen L., Viboud C., Blackwelder W.C. Researchers defend influenza vaccine study. Infectious Disease News. 2005 [Google Scholar]

58. Wilde J.A., McMillan J.A., Serwint J. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA. 1999;281:908–913. [PubMed] [Google Scholar]

59. Elder A.G., O’Donnell B., McCruden E.A. Incidence and recall of influenza in a cohort of Glasgow healthcare workers during the 1993-4 epidemic: results of serum testing and questionnaire. BMJ. 1996;313:1241–1242. [PMC free article] [PubMed] [Google Scholar]

60. Potter J., Stott D.J., Roberts M.A. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis. 1997;175:1–6. [PMC free article] [PubMed] [Google Scholar]

61. Carman W.F., Elder A.G., Wallace L.A. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet. 2000;355:93–97. [PubMed] [Google Scholar]

62. Bright R.A., Shay D.K., Shu B. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 2006;295:891–894. [PubMed] [Google Scholar]

63. Kiso M., Mitamura K., Sakai-Tagawa Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759–765. [PubMed] [Google Scholar]

64. Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons. Wkly Epidemiol Rec. 2007;82:149–150. [PubMed] [Google Scholar]

65. Beigel J.H., Farrar J., Han A.M. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374–1385. [PubMed] [Google Scholar]

66. Whitley R.J., Hayden F.G., Reisinger K.S. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127–133. [PubMed] [Google Scholar]

67. Treanor J.J., Hayden F.G., Vrooman P.S. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial: US Oral Neuraminidase Study Group. JAMA. 2000;283:1016–1024. [PubMed] [Google Scholar]

68. Monto A.S., Webster A., Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother. 1999;44(Suppl B):23–29. [PubMed] [Google Scholar]

69. Jefferson T., Deeks J.J., Demicheli V. Amantadine and rimantadine for preventing and treating influenza A in adults. Cochrane Database Syst Rev. 2004 CD001169. [PubMed] [Google Scholar]

70. Aoki F.Y., Macleod M.D., Paggiaro P. Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob Chemother. 2003;51:123–129. [PubMed] [Google Scholar]

71. Lalezari J., Campion K., Keene O., Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med. 2001;161:212–217. [PubMed] [Google Scholar]

72. Kaiser L., Wat C., Mills T. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667–1672. [PubMed] [Google Scholar]

73. de Jong M.D., Thanh T.T., Khanh T.H. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005;353:2667–2672. [PubMed] [Google Scholar]

74. Govorkova E.A., Ilyushina N.A., Boltz D.A. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother. 2007;51:1414–1424. [PMC free article] [PubMed] [Google Scholar]

75. Mandell L.A., Wunderink R.G., Anzueto A. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72. [PMC free article] [PubMed] [Google Scholar]

76. Coles F.B., Balzano G.J., Morse D.L. An outbreak of influenza A (H3N2) in a well immunized nursing home population. J Am Geriatr Soc. 1992;40:589–592. [PubMed] [Google Scholar]

77. Drinka P.J., Gravenstein S., Krause P. Outbreaks of influenza A and B in a highly immunized nursing home population. J Fam Pract. 1997;45:509–514. [PubMed] [Google Scholar]

78. Arden N.H., Patriarca P.A., Fasano M.B. The roles of vaccination and amantadine prophylaxis in controlling an outbreak of influenza A (H3N2) in a nursing home. Arch Intern Med. 1988;148:865–868. [PubMed] [Google Scholar]

79. Dolin R., Reichman R.C., Madore H.P. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982;307:580–584. [PubMed] [Google Scholar]

80. Peters P.H., Jr, Gravenstein S., Norwood P. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc. 2001;49:1025–1031. [PubMed] [Google Scholar]

81. Schilling M., Povinelli L., Krause P. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine. 1998;16:1771–1774. [PubMed] [Google Scholar]

82. Gravenstein S., Drinka P., Osterweil D. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. J Am Med Dir Assoc. 2005;6:359–366. [PubMed] [Google Scholar]

83. Mancini G.B., Etminan M., Zhang B. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47:2554–2560. [PubMed] [Google Scholar]

84. Schlienger R.G., Fedson D.S., Jick S.S. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy. 2007;27:325–332. [PubMed] [Google Scholar]

85. Mortensen E.M., Restrepo M.I., Anzueto A., Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res. 2005;6:82. [PMC free article] [PubMed] [Google Scholar]

86. Majumdar S.R., McAlister F.A., Eurich D.T. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 2006;333:999. Epub 2006 Oct 23. [PMC free article] [PubMed] [Google Scholar]

87. Fedson D.S. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis. 2006;43:199–205. [PMC free article] [PubMed] [Google Scholar]

Which of the following patients is at a greatest risk for complications caused by influenza virus?

Which of the following signs or symptoms is characteristic of an infection with the flu virus?

Which of the following is bacteria resistant to most antibiotics and causes skin abscesses?

When forming your general impression of a patient with a medical complaint it is important to remember that quizlet?